Evidence map›Paper›PMID 40081960›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2025

Tumor Asphericity in FDG PET Is an Independent Prognostic Parameter Improving Risk Stratification in Patients with Head and Neck Squamous Cell Carcinoma.

Patrick Hausmann, Sebastian Zschaeck, Christian Furth, Pavel Nikulin, Paulina Cegla, Siyer Roohani, Elia Lombardo, Joanna Kazmierska, Nathalie L Albert, Adrien Holzgreve and 10 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Patrick HausmannDepartment of Radiation Oncology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; patrick.hausmann@charite.de.
Sebastian ZschaeckDepartment of Radiation Oncology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Christian FurthDepartment of Nuclear Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Pavel NikulinInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Paulina CeglaDepartment of Nuclear Medicine, Greater Poland Cancer Centre, Poznan, Poland.
Siyer RoohaniDepartment of Radiation Oncology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Elia LombardoDepartment of Radiation Oncology, LMU University Hospital, LMU Munich, Munich, Germany.
Joanna KazmierskaElectroradiology Department, University of Medical Sciences, Poznan, Poland.
Nathalie L AlbertDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Adrien HolzgreveDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Iosif StrouthosDepartment of Radiation Oncology, German Oncology Center, European University Cyprus, Limassol, Cyprus.
Claus BelkaDepartment of Radiation Oncology, LMU University Hospital, LMU Munich, Munich, Germany.
Guillaume LandryDepartment of Radiation Oncology, LMU University Hospital, LMU Munich, Munich, Germany.
Witold CholewinskiDepartment of Nuclear Medicine, Greater Poland Cancer Centre, Poznan, Poland.
Jorg KotzerkeDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Michael BaumannOncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Mechthild KrauseDepartment of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Daniel ZipsDepartment of Radiation Oncology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Jörg van den HoffInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Frank HofheinzInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor asphericity in

Indexed as

Fluorodeoxyglucose F18Head and Neck NeoplasmsPositron-Emission TomographySquamous Cell Carcinoma of Head and NeckAdultAgedFemaleGlycolysisHumansMaleMiddle AgedPrognosisRadiopharmaceuticalsRetrospective StudiesRisk AssessmentTumor BurdenFluorodeoxyglucose F18RadiopharmaceuticalsasphericityFDG PEThead and neck squamous cell carcinomametabolic tumor volumeradiotherapy

Identifiers

PMID40081960
PMCPMC12051765

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.